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Therapy of Inflammatory Bowel Disease 
Crohn’s disease and ulcerative colitis cause significant morbidity in the pediatric 
age group. The precise etiology of inflammatory bowel disease remains unknown; 
therefore, our therapeutic efforts continue to be directed toward controlling the 
symptoms. Current therapy for inflammatory bowel disease is focused on the use 
of steroids because of their anti-inflammatory effect. Unfortunately, chronic ste- 
roid use is associated with significant and serious side effects such as increased 
blood pressure, fluid retention, bone thinning, and delayed growth. In an attempt 
to avoid these undesirable consequences, there has been a search for other anti- 
inflammatory agents. 
6-Mercaptopurine and Azathioprine 
6-Mercaptopurine (6MP) and its precursor azathioprine have been shown to have 
benefits in treating inflammatory bowel disease. These agents are purine antag- 
onists that are capable of inhibiting DNA and RNA synthesis and seem to be 
effective, especially when given for several months. They are cytotoxic to stimu- 
lated lymphoid cell lines, especially natural killer and suppressor cytotoxic cells. 
These effects are expressed clinically in adults with inflammatory bowel disease 
by a marked reduction in lymphocyte-mediated cytotoxicity, which is first seen 
after about 1 month of treatment and reaches a maximum effect after 4 to 5 
months. This time interval corresponds closely to the period of time often required 
before beneficial effects of these medications are seen in patients with intracta- 
ble Crohn’s disease. It is important to note that these medicines may reduce ste- 
roid use over a long period of time but are not helpful in an acute exacerbation. 
Although the steroid-sparing effects of these medications have been widely 
accepted in the treatment of adult patients with inflammatory bowel disease, cli- 
nicians responsible for care of pediatric patients with inflammatory bowel dis- 
ease have been slow to adopt them. Fears of toxicity come from experience in 
treatment of childhood leukemias and suppression of rejection in transplant pa- 
tients However, in these conditions, such side effects as reversible bone mar- 
row suppression, hepatotoxicity, and immune suppression are most commonly 
seen when 6MP is prescribed at doses of > 2 mg/kg per day, which is some- 
what higher than most physicians use in treating pediatric patients with inflam- 
matory bowel disease. Because these drugs interfere with DNA synthesis and 
exert a long-standing cytostatic effect on lymphoid cells, concerns have been 
raised about long-term risk of malignancies. However, studies in adult patients 
have not confirmed the risks. Experience with 6MP in the range that is used to 
treat inflammatory bowel disease, in the range of 1 to 2 mg/kg per day, is not 
widely available in the pediatric patient; however, preliminary studies in pediat- 
ric patients suggest that this drug is effective in reducing steroid dosage.’ 
6MP needs to be studied in a controlled fashion to determine its efficacy and 
Craig Hillemeier, MD, is Director of Pediatric Gastroenterology at C. S. Mott Children’s Hos- 
pital, University of Michigan Medical Center, Ann Arbor. 
96/l/44866 
Current Problems in Pediatrics ! April 1993 143 
New Developments 
safety in the treatment of childhood inflammatory bowel disease, and these trials 
are currently under way. It is likely the steroid-sparing effects of these agents 
will be a welcome addition to the pharmacologic means of controlling childhood 
inflammatory bowel disease. 
Sulfasalazine and Its Derivatives 
Sulfasalazine is the acid azo compound of 5aminosalicylic acid (5-ASA) and sul- 
fapyridine. Sulfasalazine has been shown to be an effective agent in preventing 
and treating recurrence of ulcerative colitis and may have a therapeutic role in 
managing Crohn’s disease. Its efficacy is restricted in 10% to 15% of pediatric 
patients because of the skin reaction to the sulfa component, and many patients 
experience significant gastrointestinal upset. Studies have shown that the salic- 
ylate portion of sulfasalazine is the therapeutically active component. This salic- 
ylate component likely has its therapeutic effect by interfering with prostaglandin 
and leukotriene synthesis, which are thought to be essential intermediates in the 
inflammatory process. 
Because many of the adverse effects of Azulfidine are ascribed to the sulfa 
function of the compound, which is thought to be inactive, there have been re- 
cent attempts to delete the sulfa component. A variety of delivery vehicles for 
the salicylate moiety have recently been developed, and formulations of 5-ASA 
can be administered either orally or rectally. The salicylate preparation by itself 
has recently become available in an oral preparation of a 5-aminosalicylate mol- 
ecule bound to another 5-aminosalicylate molecule by a diazo bond without the 
sulfa component. Colonic bacteria then cleave this diazo bond in the colon, sim- 
ilar to Azulfidine, and the 5-ASA is liberated to act locally on inflamed colonic 
epithelium. Studies suggest similar efficacy to Azulfidine. This drug, known as 
dipentum, appears to be well tolerated, does not cause the immediate hyper- 
sensitivity skin reaction seen in response to the sulfa, appears to cause less gas- 
trointestinal upset, and has been shown to be comparable in efficacy to Azulfi- 
dine in treating inflammatory bowel disease.’ 
Rectally administered formulations that allow a higher concentration of 5-ASA 
to be obtained in the rectum and recta-sigmoid than can be obtained with oral 
medication have been developed. They are currently available in the United 
States as a 4 gm enema and 250 mg suppositories. In adult patients, the rectal 
forms appear to be a valuable form of therapy in distal and left-sided colitis, De- 
termination of the exact role and dosage of these 5-ASA preparations, both rec- 
tal and oral, in the management of children with inflammatory bowel disease is 
currently under way. 
Ulcer Disease Associated With Nonsteroidal Anti-inflammatory Drugs 
Gastrointestinal tract ulceration associated with nonsteroidal anti-inflammatory 
drugs (NSAIDs) is commonly seen in pediatric populations in which such agents 
are chronically required. It has been estimated that the risk of a gastric ulcer in a 
patient on NSAlDs (i.e., aspirin) is about 40 times greater than that of the gen- 
eral population, and chronic ingestion of NSAiDs is associated with the develop- 
ment of mucosal ulceration in 10% to 20% of patients. Although these ulcers may 
occur at any time, they usually appear after at least 3 months of NSAID inges- 
tion It is hypothesized that these ulcers result from the systemic effects of the 
nonsteroidal anti-inflammatory drugs on the mucosal defense mechanisms. Some 
evidence suggests they result in decreased mucosal prostaglandin production. 
It is important to note that although many patients who develop mucosal inflam- 
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mation on NSAlDs will have obvious abdominal symptoms, it is not infrequent for 
mucosal lesions to develop in the absence of overt gastrointestinal symptoms. 
Although the ulcerations respond rapidly to conventional therapy if the agents 
are discontinued, in many patients this is not possible. H2-receptor antagonists 
may be successful in treating these lesions, but a prostaglandin El analogue, 
misoprostol, has been licensed in this country for the treatment of such lesions. 
The mechanisms by which these prostaglandins enhance mucosal protection in- 
clude decreased gastric acid secretion, increased mucus secretion, bicarbon- 
ate secretion, blood flow, and epithelial regeneration. Although experience in chil- 
dren is limited, these prostaglandins have been demonstrated to be efficacious 
in the prevention of NSAID-associated gastric lesions in adults3 The most com- 
mon side effect of misoprostol is diarrhea and gastrointestinal upset. 
Misoprostol also has been found to increase the efficiency of fat absorption 
in patients with cystic fibrosis4 Although the precise mechanism is unclear, it is 
thought that the increased bicarbonate production seen with the prostaglandin 
analogue reduces intraluminal pH and allows the exogenously taken pancreatic 
enzyme to be more effective. 
Abdominal Pain, Ulcer Disease, and Helicobacter 
Although abdominal pain is a common complaint in pediatrics and peptic ulcer 
disease is frequently considered in the differential diagnosis, it is not common to 
find abdominal pain that is caused by clearly defined ulcers. When seen, gastric 
or duodenal ulcer disease is classified as either primary (idiopathic) or, more 
commonly seen, secondary to medications or systemic illness. 
In evaluating patients with primary peptic ulcer disease, it has been found 
that many patients with duodenal ulcers, gastritis, or both will have evidence of 
bacterial colonization in the upper gastrointestinal tract. The strain was initially 
identified by its histologic appearance of silver stains of gastric antral biopsies. 
The organism, which was initially named a Campylobacter because of its mor- 
phologic resemblance to other Campylobacter bacteria, has been reclassified 
on the basis of genetic information as Helicobacter pylori. 
Although most patients with primary duodenal ulcer disease have evidence 
of the organism H. pylori in the gastric antrum, it is not true that all patients with 
H. py/ori in the gastric antrum will have ulcer disease. When this organism is pre- 
sent in the gastric antrum in the absence of duodenal ulcer disease, its associ- 
ation with pathology such as abdominal pain is less certain, but it has been as- 
sociated with histologic evidence of gastritis5 There is some evidence that in 
adults, the severity of symptoms correlates with the degree of histologic inflam- 
mation One feature that has made it difficult to determine the precise relation- 
ship between the presence of this organism, gastritis, and clinical symptoms is 
that the histologic finding of gastritis by the pathologist on microscopic exami- 
nation of antral biopies correlates very poorly with the presence or absence of 
inflammation of gastric mucosa as either seen by an endoscopist or evaluated 
by contrast radiography during an upper gastrointestinal series. To further com- 
plicate the issue, the presence of H. pylori and its relationship to abdominal pain 
symptoms must be interpreted with caution, because it has also been found in 
antral biopsies of patients with no gastrointestinal symptoms. It also is worthy to 
note that H. pylori in gastric antral tissue is seen increasingly with advancing age, 
and it is quite common to see it within the sixth decade of life, even in people 
with no gastrointestinal tract inflammation. 
Currently a diagnosis of H. pylon’ is best made by histologic examination of 
the gastric biopsy, although a gel test that turns color in response to the increased 
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urease activity of the organism is helpful, and increasingly sensitive serologic 
tests for antibodies to Helicobacter are becoming available. The treatment of pos- 
sible H. py/ori must be undertaken with caution, because the relationship between 
clinical symptoms and the actual presence of the organism is oftentimes unclear, 
especially in the absence of duodenal ulcer disease. Triple therapy, which con- 
sists of a bismuth compound, antibiotics, and HZ antagonist, has been shown to 
eradicate the organism in a high percentage of cases. 
Hepatitis 
During the past 2 years, it has become apparent that a large number of hepatitis 
cases thought to be infectious in etiology but without supporting serologic evi- 
dence for hepatitis A or B are caused by a virus now known as hepatitis C. Hep- 
atitis C virus contains a positive-strand RNA molecule and appears to be related 
to flaviviruses or togavirus. A majority of the cases of transfusion-related hepati- 
tis that are non-A, non-B appear to be caused by hepatitis C. Many, but not all, 
donors capable of transmitting hepatitis C will have evidence of elevated ALT, 
and before the emergence of a specific antibody test, an elevated ALT was used 
as a screening test in the hope of reducing the incidence of transfusion- 
associated hepatitis. The current test for hepatitis C depends on an antibody to 
the virus that is not as precise as the antigenic markers of viral replication cur- 
rently available in hepatitis B, and therefore our knowledge of this organism is 
less complete.6 
The antibody test for hepatitis C has become available only recently; there- 
fore, patients who have required large numbers of blood transfusions are often 
found to be infected with hepatitis C virus. Because these blood products have 
been efficiently screened for hepatitis 8, it is not surprising that hepatitis C virus 
infection accounts for most of the chronic liver disease observed in this popula- 
tion. There is also evidence of vertical transmission of hepatitis C from mother to 
child, although the role of this perinatally acquired infection is unclear. 
It appears that the hepatitis C virus is much less infectious than the hepatitis 
B virus. Relatively large quantities of infective material are necessary for infec- 
tion. It has been estimated that half of the people infected with hepatitis C will 
develop chronic hepatitis for at least a year and that 20% will eventually develop 
cirrhosis. Current therapy is primarily supportive, although interferon has had 
some possible successes in adults. In most epidemiologic studies to date, 40% 
of non-A, non-B hepatitis cases do not have an identifiable source. 
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